Trivalent Influenza Vaccine

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Influenza

Conditions

Influenza, Healthy

Trial Timeline

Jun 1, 2015 → Jan 1, 2016

NCT ID

NCT02473510

About Trivalent Influenza Vaccine

Trivalent Influenza Vaccine is a approved stage product being developed by AstraZeneca for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT02473510. Target conditions include Influenza, Healthy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02473510	Approved	Completed	Jun 1, 2015	Jan 1, 2016	Influenza
NCT01859143	Approved	Completed	May 1, 2013	Dec 1, 2013	Influenza

Competing Products

20 competing products in Influenza

See all competitors

Product	Company	Stage	Hype Score
Influenza vaccine, split inactivated	Comac Medical	Phase 1	25
Vaccine	Comac Medical	Phase 3	69
CT-P27 90 mg/kg + CT-P27 45 mg/kg + Placebo	Celltrion	Phase 2	52
CT-P27 + Placebo	Celltrion	Phase 2	52
CAIV-T	Pfizer	Phase 3	76
CS-8958 + CS-8958 + oseltamivir phosphate	Daiichi Sankyo	Phase 3	77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir	Shionogi	Phase 3	77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir	Shionogi	Phase 3	77
fH1 2 ug + fH1 8 ug + DSP-0546LP 2.5 ug + DSP-0546LP 5 ug + DSP-0546LP 10 ug + Placebo	Sumitomo Pharma	Phase 1	33
Monovalent Influenza Vaccine	AstraZeneca	Approved	85
Monovalent Influenza Vaccine	AstraZeneca	Approved	85
AZD4117 + AZD5315	AstraZeneca	Phase 1/2	41
Trivalent Influenza Vaccine	AstraZeneca	Approved	85
FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)	AstraZeneca	Approved	85
Trivalent Influenza Virus Vaccine	AstraZeneca	Approved	85
Comparator: Modified Process Vaccine + Comparator: COMVAX™	Merck	Phase 3	77
Molnupiravir + Placebo molnupiravir + Placebo oseltamivir + Oseltamivir + Influenza A Virus	Merck	Phase 1	33
V512 + Comparator: Placebo to V512	Merck	Phase 1	33
Vaxelis + PedvaxHIB	Merck	Approved	85
Seasonal Influenza Vaccine	Novartis	Phase 2	52

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved